Eton Pharmaceuticals, Inc. Chief Business Officer David Krempa exercised 10,000 Restricted Stock Units, converting them into an equal number of shares of common stock. These RSUs were part of a 40,000-unit grant awarded on July 12, 2022 that vests in four equal annual installments beginning July 12, 2023. Following this vesting-related exercise, Krempa holds 37,025 common shares directly.
Opaleye Management Inc., a 10% owner of Eton Pharmaceuticals, Inc., reported open-market sales totaling 126,685 shares of common stock from July 2 to July 7, 2026. The trades were executed at weighted average prices around $37–$38 per share.
Shares were sold through Opaleye, L.P. and a separately managed account for which Opaleye Management serves as investment manager or portfolio manager. After these transactions, Opaleye, L.P. held 2,680,000 shares, and the managed account held 53,315 shares. Opaleye Management states it may be deemed to beneficially own these securities but disclaims beneficial ownership except to the extent of its pecuniary interest.
Krempa David reported acquisition or exercise transactions in this Form 4 filing.
Eton Pharmaceuticals Chief Business Officer David Krempa received a grant of 10,000 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Eton common stock. These RSUs vest in four equal annual installments starting on June 26, 2027, as long as he remains employed on each vesting date.
Following this award, Krempa directly holds a reported total of 96,829 derivative-based shares tied to Eton common stock. This filing reflects a compensation-related equity grant rather than an open-market purchase or sale.
ETON affiliate disclosed proposed sales of common stock under Section 144 and related issuer transfers, listing multiple grant-related issuances and recent dispositions by James R. Gruber. The filing lists a 25000-share sale on 06/25/2026, a 25000-share sale on 06/23/2026, and a 3,117-share sale on 06/02/2026.
The record also shows issuer-side stock option exercises and ESPU/RSU cash settlements with discrete share counts and dates through 06/26/2026.
ETON submitted a Form 144 filing reporting a proposed sale of 25,000 shares related to a stock option exercise dated 06/25/2026. The filing lists the broker Raymond James & Associates and indicates cash proceeds.
It also discloses prior sales in the past three months: 25,000 shares on 06/23/2026 for $831,674.00 and 3,117 shares on 06/02/2026 for $84,041.00.
ETON insider filed a Form 144 to sell 25,000 shares. The filing lists a stock option exercise for 25,000 common shares to be sold for cash on 06/23/2026. The filing also reports a prior sale of 3,117 shares on 06/02/2026 for $84,041.00.
Eton Pharmaceuticals director Jennifer McKie Adams reported an option exercise paired with an open-market sale of common stock. She exercised employee stock options for 50,000 shares of common stock at an exercise price of $3.78 per share, then sold 50,000 shares in open-market transactions at a weighted average price of $32.4759 per share.
The sale was executed in multiple trades at prices ranging from $32.10 to $32.71, and the option grant, which vested quarterly, was fully vested by February 7, 2023. Following these transactions, Adams reported no remaining holdings of common stock or employee stock options.
Eton Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders virtually on June 9, 2026. Stockholders elected Jenn Adams and Charles J. Casamento to the board for three-year terms and ratified Grant Thornton LLP as independent registered public accounting firm for the year ending December 31, 2026.